These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 8108873)

  • 1. Induction immunosuppression with antilymphocyte globulin or OKT3 in cadaver kidney transplantation. Results of a single institution prospective randomized trial.
    Hanto DW; Jendrisak MD; So SK; McCullough CS; Rush TM; Michalski SM; Phelan D; Mohanakumar T
    Transplantation; 1994 Feb; 57(3):377-84. PubMed ID: 8108873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antilymphocyte globulin versus OKT3 induction therapy in cadaveric kidney transplantation: a prospective randomized study.
    Grino JM; Castelao AM; Serón D; Gonzalez C; Galceran JM; Gil-Vernet S; Andrés E; Mestre M; Torras J; Alsina J
    Am J Kidney Dis; 1992 Dec; 20(6):603-10. PubMed ID: 1462990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OKT3 for primary therapy of the first rejection episode in kidney transplants.
    Tesi RJ; Elkhammas EA; Henry ML; Ferguson RM
    Transplantation; 1993 May; 55(5):1023-9. PubMed ID: 8497875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective randomized comparison of quadruple versus triple therapy for first cadaver transplants with immediate function.
    Slakey DP; Johnson CP; Callaluce RD; Browne BJ; Zhu YR; Roza AM; Adams MB
    Transplantation; 1993 Oct; 56(4):827-31. PubMed ID: 8212201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation.
    Clark G; Walsh G; Deshpande P; Koffman G
    Nephrol Dial Transplant; 2002 Jul; 17(7):1304-9. PubMed ID: 12105256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The risk of infection following OKT3 and antilymphocyte globulin treatment for renal transplant rejection: results of a single center prospectively randomized trial.
    Hesse UJ; Wienand P; Baldamus C; Pollok M; Pichlmaier H
    Transpl Int; 1992; 5 Suppl 1():S440-3. PubMed ID: 14621840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of the Minnesota randomized prospective trial of cyclosporine versus azathioprine-antilymphocyte globulin for immunosuppression in renal allograft recipients.
    Sutherland DE; Fryd DS; Strand MH; Canafax DM; Ascher NL; Payne WD; Simmons RL; Najarian JS
    Am J Kidney Dis; 1985 Jun; 5(6):318-27. PubMed ID: 3893106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of OKT3 in cadaveric renal transplantation for rejection that is unresponsive to conventional anti-rejection therapy.
    Norman DJ; Barry JM; Bennett WM; Leone M; Henell K; Funnell B; Hubert B
    Am J Kidney Dis; 1988 Feb; 11(2):90-3. PubMed ID: 3124611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antilymphocyte globulins versus OKT3 as prophylactic treatment in highly sensitized renal transplant recipients.
    Vela C; Cristol JP; Chong G; Okamba A; Lorho R; Mion C; Mourad G
    Transpl Int; 1994; 7 Suppl 1():S259-62. PubMed ID: 11271219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective randomized controlled trial of initial immunosuppression with ALG versus OKT3 in recipients of cardiac allografts.
    Menkis AH; Powell AM; Novick RJ; McKenzie FN; Kostuk WJ; Pflugfelder PW; Brown JE; Rochon J; Chow LH; Stiller C
    J Heart Lung Transplant; 1992; 11(3 Pt 1):569-76. PubMed ID: 1610866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antilymphocyte globulin with a small dose of cyclosporine A and prednisone as the induction of immunosuppression in renal allograft recipients.
    Boratyńska M; Szepietowski T; Szewczyk Z; Szydłowski Z
    Arch Immunol Ther Exp (Warsz); 1992; 40(2):163-8. PubMed ID: 1299176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of rabbit antithymocyte serum and OKT3 as prophylaxis against renal allograft rejection.
    Cole EH; Cattran DC; Farewell VT; Aprile M; Bear RA; Pei YP; Fenton SS; Tober JA; Cardella CJ
    Transplantation; 1994 Jan; 57(1):60-7. PubMed ID: 8291115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of OKT3 with ALG for prophylaxis for patients with acute renal failure after cadaveric renal transplantation.
    Steinmuller DR; Hayes JM; Novick AC; Streem SB; Hodge E; Slavis S; Martinez A; Graneto D; Pearce G
    Transplantation; 1991 Jul; 52(1):67-71. PubMed ID: 1677502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The incidence and impact of early rejection episodes on graft outcome in recipients of first cadaver kidney transplants.
    Gulanikar AC; MacDonald AS; Sungurtekin U; Belitsky P
    Transplantation; 1992 Feb; 53(2):323-8. PubMed ID: 1738926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential antilymphocyte globulin/cyclosporine immunosuppression in cadaveric renal transplantation. Effect of duration of ALG therapy.
    Stratta RJ; D'Alessandro AM; Armbrust MJ; Pirsch JD; Sollinger HW; Kalayoglu M; Belzer FO
    Transplantation; 1989 Jan; 47(1):96-102. PubMed ID: 2643236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quadruple immunosuppression: comparison of OKT3 and Minnesota antilymphocyte globulin.
    Light JA; Khawand N; Aquino A; Ali A; Korb S
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):10-3. PubMed ID: 2510505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OKT3 salvage therapy in a quadruple immunosuppressive protocol in cadaveric renal transplantation.
    D'Alessandro AM; Pirsch JD; Stratta RJ; Sollinger HW; Kalayoglu M; Maki DG; Belzer FO
    Transplantation; 1989 Feb; 47(2):297-300. PubMed ID: 2493176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. OKT3 prophylaxis in cadaveric kidney transplant recipients with delayed graft function.
    Cohen DJ; Benvenisty AI; Cianci J; Hardy MA
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):19-27. PubMed ID: 2510507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential therapy--a prospective randomized trial of MALG versus OKT3 for prophylactic immunosuppression in cadaver renal allograft recipients.
    Frey DJ; Matas AJ; Gillingham KJ; Canafax D; Payne WD; Dunn DL; Sutherland DE; Najarian JS
    Transplantation; 1992 Jul; 54(1):50-6. PubMed ID: 1631944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Symptomatic cytomegalovirus infection in renal transplant recipients given either Minnesota antilymphoblast globulin (MALG) or OKT3 for rejection prophylaxis.
    Bailey TC; Powderly WG; Storch GA; Miller SB; Dunkel JD; Woodward RS; Spitznagel E; Hanto DW; Dunagan WC
    Am J Kidney Dis; 1993 Feb; 21(2):196-201. PubMed ID: 8381577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.